Omega Therapeutics IPO Presentation Deck

Insulated Genomic Domains IGDS present differentially in pristine and diseased states and the OMEGA platform leverages this knowledge for potential therapeutic interventions Example of IGD Control Pristine IGD Enhancer/Repressor sequence mRNA CTCF- CTCF binding site -Promoter mRNA -Gene IGD with structural alteration ©2021 Omega Therapeutics, Inc. OEC Overexpressed mRNA Over- expressed gene DNA Overexpress protein Ribosome Additional enhancer Aberrant CTCF binding OEC corrects aberrant binding OEC correcting aberrant CTCF binding Correct CTCF binding site IGD restored to pristine state Restored CTCF binding Normal prote expression Normal mRNA expression Extraneous, functional IGD alterations (e.g., due to pathogenic insults, oxidative stress, etc.) could also be corrected OEC natura degradation 10

View entire presentation